BR112015005351A2 - sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior - Google Patents
sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferiorInfo
- Publication number
- BR112015005351A2 BR112015005351A2 BR112015005351A BR112015005351A BR112015005351A2 BR 112015005351 A2 BR112015005351 A2 BR 112015005351A2 BR 112015005351 A BR112015005351 A BR 112015005351A BR 112015005351 A BR112015005351 A BR 112015005351A BR 112015005351 A2 BR112015005351 A2 BR 112015005351A2
- Authority
- BR
- Brazil
- Prior art keywords
- bladder
- methods
- drug delivery
- trospium
- delivery systems
- Prior art date
Links
- 238000012377 drug delivery Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 208000026723 Urinary tract disease Diseases 0.000 title abstract 2
- 230000004064 dysfunction Effects 0.000 title abstract 2
- 208000014001 urinary system disease Diseases 0.000 title abstract 2
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 abstract 4
- 229960001491 trospium Drugs 0.000 abstract 4
- 229940079593 drug Drugs 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 206010069632 Bladder dysfunction Diseases 0.000 abstract 1
- 210000005068 bladder tissue Anatomy 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Anesthesiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
Abstract
resumo sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior métodos, dispositivos e medicamentos que incluem tróspio são fornecidos para uso no tratamento de disfunção da bexiga administrando localmente o tróspio na bexiga para atingir uma concentração sustentada de tróspio na urina na bexiga suficiente para produzir uma concentração terapêutica de tróspio no tecido da bexiga. a droga pode ser distribuída para a bexiga de um dispositivo de distribuição de droga intravesical inserido na bexiga, em que o dispositivo libera continuamente a droga para a urina na bexiga durante um período prolongado de horas ou dias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261702576P | 2012-09-18 | 2012-09-18 | |
| PCT/US2013/060479 WO2014047221A1 (en) | 2012-09-18 | 2013-09-18 | Drug delivery systems and methods for treatment of bladder voiding dysfunction|and other lower urinary tract disorders by using trospium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015005351A2 true BR112015005351A2 (pt) | 2017-07-04 |
Family
ID=49301639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015005351A BR112015005351A2 (pt) | 2012-09-18 | 2013-09-18 | sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10500200B2 (pt) |
| EP (1) | EP2897616A1 (pt) |
| JP (2) | JP6600256B2 (pt) |
| KR (1) | KR102141433B1 (pt) |
| CN (2) | CN111450093A (pt) |
| AU (1) | AU2013318146B2 (pt) |
| BR (1) | BR112015005351A2 (pt) |
| CA (1) | CA2883855C (pt) |
| IL (1) | IL237498B (pt) |
| MX (2) | MX379066B (pt) |
| RU (1) | RU2670749C9 (pt) |
| SG (1) | SG11201502104YA (pt) |
| WO (1) | WO2014047221A1 (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
| BR112015003836A2 (pt) | 2012-08-31 | 2017-07-04 | Taris Biomedical Llc | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga |
| WO2014036556A2 (en) | 2012-08-31 | 2014-03-06 | Taris Biomedical, Inc. | Drug delivery systems and methods for treatment of prostate |
| CN111450093A (zh) * | 2012-09-18 | 2020-07-28 | 塔里斯生物医药公司 | 通过使用曲司铵来治疗膀胱排尿功能障碍和其它下泌尿道病症的药物递送系统和方法 |
| EP3183026B1 (en) | 2014-08-19 | 2019-10-30 | The Regents of The University of California | Implants for localized drug delivery and methods of use thereof |
| GB201506526D0 (en) | 2015-04-17 | 2015-06-03 | Uropharma Ltd And Synesis Llc | Medicinal composition |
| CN106706832A (zh) * | 2015-08-06 | 2017-05-24 | 舒泰神（北京）生物制药股份有限公司 | 一种测定曲司氯铵含量的方法 |
| AU2018217094B2 (en) * | 2017-02-01 | 2023-06-08 | Taris Biomedical Llc | In vivo drug delivery devices and methods for drug delivery |
| US10857173B2 (en) | 2017-07-25 | 2020-12-08 | Taris Biomedical Llc | Methods of treating tumor metastasis |
| TWI841554B (zh) | 2018-03-21 | 2024-05-11 | 丹麥商珍美寶股份有限公司 | 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法 |
| CA3099547A1 (en) | 2018-05-07 | 2019-11-14 | Reshma Abdulla RANGWALA | Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate |
| MX2021001264A (es) | 2018-08-01 | 2021-07-02 | Taris Biomedical Llc | Métodos para tratar la vejiga hiperactiva con el uso de trospio. |
| CA3138433A1 (en) * | 2019-04-30 | 2020-11-05 | Trigone Pharma Ltd. | Formulations and methods for drug instillation into the bladder and treatment of bladder ailments |
| US11338119B2 (en) | 2020-03-20 | 2022-05-24 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11344526B2 (en) | 2020-03-20 | 2022-05-31 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| US11173291B2 (en) | 2020-03-20 | 2021-11-16 | The Regents Of The University Of California | Implantable drug delivery devices for localized drug delivery |
| KR102596697B1 (ko) | 2021-05-20 | 2023-11-01 | 김정우 | 바위솔 추출물을 유효성분으로 포함하는 화장품 조성물 및 그 제조 방법 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE172117T1 (de) | 1996-11-27 | 1998-10-15 | Pfleger R Chem Fab | Verwendung von trospiumchlorid zur herstellung eines arzneimittels zur behandlung von blasenkrankheiten |
| EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| EP1572279A1 (en) * | 2002-12-11 | 2005-09-14 | Coloplast A/S | A urinary catheter device with a pharmaceutically active composition |
| CA2513188A1 (en) | 2003-01-16 | 2004-08-05 | University Of Rochester | Quaternary antimuscarinic compounds for the treatment of bladder diseases |
| ES2322148T3 (es) | 2004-08-11 | 2009-06-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias. |
| WO2006101954A2 (en) * | 2005-03-17 | 2006-09-28 | Indevus Pharmaceuticals, Inc. | Interstitial cystitis treatment |
| US7390816B2 (en) | 2005-06-21 | 2008-06-24 | Bridge Pharma, Inc. | Methods for treating urinary incontinence in patients suffering from memory disorders |
| US20100003297A1 (en) | 2005-08-11 | 2010-01-07 | Massachusetts Institute Of Technology | Implantable Drug Delivery Device and Methods of Treating Male Genitourinary and Surrounding Tissues |
| EP1933810B1 (en) | 2005-08-11 | 2012-10-10 | Massachusetts Institute of Technology | Intravesical drug delivery device and method |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| EP2231254B9 (en) | 2007-12-11 | 2015-04-08 | Massachusetts Institute of Technology | Implantable drug delivery device |
| CN102470237A (zh) | 2009-06-26 | 2012-05-23 | 塔里斯生物医药公司 | 用于可植入药物递送装置的固体药物片剂 |
| US8721621B2 (en) | 2009-09-10 | 2014-05-13 | Taris Biomedical, Inc. | Systems and methods for deploying devices to genitourinary sites |
| US9017312B2 (en) | 2009-09-10 | 2015-04-28 | Taris Biomedical Llc | Implantable device for controlled drug delivery |
| JP2013514837A (ja) | 2009-12-17 | 2013-05-02 | タリス バイオメディカル，インコーポレイテッド | 膀胱内における耐容性を備えた植込み型装置及び治療方法 |
| US20110218488A1 (en) | 2010-03-05 | 2011-09-08 | Taris Biomedical, Inc. | Systems and Methods for Implanting Devices in the Bladder and Other Genitourinary Sites |
| WO2012048104A1 (en) | 2010-10-06 | 2012-04-12 | Taris Biomedical, Inc. | Implantable drug delivery device with bladden retention feature |
| US8690840B2 (en) | 2010-10-06 | 2014-04-08 | Taris Biomedical, Inc. | Time-selective bioresorbable or collapsible drug delivery systems and methods |
| EP2663300B1 (en) | 2011-01-10 | 2023-03-08 | TARIS Biomedical LLC | Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding |
| KR20140048086A (ko) * | 2011-02-04 | 2014-04-23 | 타리스 바이오메디컬 인코포레이티드 | 저 용해성 약물의 제어 방출을 위한 이식가능한 디바이스 |
| CN111450093A (zh) * | 2012-09-18 | 2020-07-28 | 塔里斯生物医药公司 | 通过使用曲司铵来治疗膀胱排尿功能障碍和其它下泌尿道病症的药物递送系统和方法 |
| WO2014145638A1 (en) | 2013-03-15 | 2014-09-18 | Taris Biomedical, Inc | Drug delivery devices with drug-permeable component and methods |
-
2013
- 2013-09-18 CN CN202010161062.6A patent/CN111450093A/zh active Pending
- 2013-09-18 SG SG11201502104YA patent/SG11201502104YA/en unknown
- 2013-09-18 MX MX2015003110A patent/MX379066B/es unknown
- 2013-09-18 RU RU2015112196A patent/RU2670749C9/ru active
- 2013-09-18 KR KR1020157008403A patent/KR102141433B1/ko active Active
- 2013-09-18 EP EP13771696.5A patent/EP2897616A1/en active Pending
- 2013-09-18 JP JP2015532177A patent/JP6600256B2/ja active Active
- 2013-09-18 WO PCT/US2013/060479 patent/WO2014047221A1/en active Application Filing
- 2013-09-18 CA CA2883855A patent/CA2883855C/en active Active
- 2013-09-18 AU AU2013318146A patent/AU2013318146B2/en active Active
- 2013-09-18 BR BR112015005351A patent/BR112015005351A2/pt not_active Application Discontinuation
- 2013-09-18 CN CN201380046758.2A patent/CN104684556A/zh active Pending
-
2015
- 2015-03-02 IL IL237498A patent/IL237498B/en active IP Right Grant
- 2015-03-11 MX MX2020002465A patent/MX2020002465A/es unknown
- 2015-03-16 US US14/658,699 patent/US10500200B2/en active Active
-
2018
- 2018-02-02 JP JP2018017300A patent/JP2018080208A/ja active Pending
-
2019
- 2019-12-06 US US16/706,009 patent/US11850244B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102141433B1 (ko) | 2020-08-05 |
| WO2014047221A1 (en) | 2014-03-27 |
| MX379066B (es) | 2025-03-04 |
| RU2015112196A (ru) | 2016-11-10 |
| RU2670749C2 (ru) | 2018-10-25 |
| EP2897616A1 (en) | 2015-07-29 |
| US10500200B2 (en) | 2019-12-10 |
| JP6600256B2 (ja) | 2019-10-30 |
| JP2015529688A (ja) | 2015-10-08 |
| MX2015003110A (es) | 2015-06-05 |
| US11850244B2 (en) | 2023-12-26 |
| WO2014047221A9 (en) | 2015-05-21 |
| US20200108057A1 (en) | 2020-04-09 |
| SG11201502104YA (en) | 2015-05-28 |
| US20150182516A1 (en) | 2015-07-02 |
| AU2013318146A1 (en) | 2015-03-19 |
| AU2013318146B2 (en) | 2018-05-10 |
| IL237498B (en) | 2018-01-31 |
| CN104684556A (zh) | 2015-06-03 |
| CN111450093A (zh) | 2020-07-28 |
| RU2670749C9 (ru) | 2018-12-13 |
| KR20150058271A (ko) | 2015-05-28 |
| CA2883855C (en) | 2020-09-15 |
| MX2020002465A (es) | 2020-07-13 |
| CA2883855A1 (en) | 2014-03-27 |
| JP2018080208A (ja) | 2018-05-24 |
| IL237498A0 (en) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015005351A2 (pt) | sistemas para distribuição de drogas e métodos para tratamento de disfunção de esvaziamento da bexiga e outros distúrbios do trato urinário inferior | |
| BR112015003836A2 (pt) | sistemas e métodos para distribuição de drogas para tratamento de câncer de bexiga | |
| BR112015004110A2 (pt) | sistemas e métodos de distribuição de drogas para tratamento de próstata | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| MX2012014521A (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion. | |
| EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
| EA202091999A2 (ru) | Применение ингибиторов dpp iv | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| MX2013013809A (es) | Dispositivos expandibles con revestimiento de una composicion de paclitaxel. | |
| EP4461326A3 (en) | Flexible system for delivering an anchor | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
| EP3300734A3 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| AR082312A1 (es) | Una composicion farmaceutica de combinacion para tratar diabetes y desordenes metabolicos | |
| MX362804B (es) | Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor. | |
| EA201491702A1 (ru) | Оптимизированные терапевтические агенты для подкожного введения | |
| MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. | |
| MX377897B (es) | Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso. | |
| MX2013013808A (es) | Dispositivos expandibles con revestimiento de una composicion de rapamicina. | |
| AR079000A1 (es) | Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas | |
| MX2010006724A (es) | Regimenes terapeuticos para el tratamiento de desordenes inmunoinflamatorios. | |
| MY180772A (en) | Novel therapeutic mirtazapine combinations for use in pain disorders | |
| UA109359C2 (xx) | Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном | |
| Barsotti | CMV lung infection, bladder infection and erythematous rash: 3 case reports |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |